Comparing the area under the curve and peak height methods in the calculation of FLT3-ITD allelic ratio
Corresponding Author
Pietro Di Ciaccio
Department of Haematology, Liverpool Hospital, Sydney, NSW, Australia
Correspondence
Pietro Di Ciaccio, Level 5 Haematology, The Kinghorn Cancer Centre, 370 Victoria St, Darlinghurst NSW 2010, Australia.
Email: [email protected]
Search for more papers by this authorAnabel Kearney
Ingham Institute for Applied Medical Research, Sydney, NSW, Australia
Search for more papers by this authorSilvia Ling
Department of Haematology, Liverpool Hospital, Sydney, NSW, Australia
Ingham Institute for Applied Medical Research, Sydney, NSW, Australia
Search for more papers by this authorCorresponding Author
Pietro Di Ciaccio
Department of Haematology, Liverpool Hospital, Sydney, NSW, Australia
Correspondence
Pietro Di Ciaccio, Level 5 Haematology, The Kinghorn Cancer Centre, 370 Victoria St, Darlinghurst NSW 2010, Australia.
Email: [email protected]
Search for more papers by this authorAnabel Kearney
Ingham Institute for Applied Medical Research, Sydney, NSW, Australia
Search for more papers by this authorSilvia Ling
Department of Haematology, Liverpool Hospital, Sydney, NSW, Australia
Ingham Institute for Applied Medical Research, Sydney, NSW, Australia
Search for more papers by this author
REFERENCES
- 1Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99(12): 4326-4335.
- 2Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000; 19(5): 624-631.
- 3Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European leukemianet AML working party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012; 9(10): 579-590.
- 4Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008; 111(5): 2776-2784.
- 5Ho AD, Schetelig J, Bochtler T, et al. Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD. Biol Blood Marrow Transplant. 2016; 22(3): 462-469.
- 6Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014; 124(23): 3441-3449.
- 7Hirsch P, Labopin M, Marzac C, et al. Impact of FLT3-ITD mutational burden in 469 Acute Myeloid Leukemia (AML) patients. Blood. 2014; 124(21): 1033.
10.1182/blood.V124.21.1033.1033 Google Scholar
- 8Pratcorona M, Brunet S, Nomdedeu J, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013; 121(14): 2734-2738.
- 9Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4): 424-447.
- 10 FLT-ITD Survey Report. Royal College of Pathologists Australiasia Quality Assurance Programs; 21 December 201.
- 11Kim Y, Lee GD, Park J, et al. Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length. Blood Cancer J. 2015; 5: e336.
- 12Buban T, Koczok K, Foldesi R, et al. Detection of internal tandem duplications in the FLT3 gene by different electrophoretic methods. Clin Chem Lab Med. 2011; 50(2): 301-310.
